Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24.

Gupta PK, Mukherjee P, Dhawan S, Pandey AK, Mazumdar S, Gaur D, Jain SK, Chauhan VS.

Clin Vaccine Immunol. 2014 Jun;21(6):886-97. doi: 10.1128/CVI.00179-14.

2.

Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response.

Mazumdar S, Mukherjee P, Yazdani SS, Jain SK, Mohmmed A, Chauhan VS.

Infect Immun. 2010 Feb;78(2):872-83. doi: 10.1128/IAI.00427-09.

3.

Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.

Sachdeva S, Mohmmed A, Dasaradhi PV, Crabb BS, Katyal A, Malhotra P, Chauhan VS.

Vaccine. 2006 Mar 15;24(12):2007-16.

PMID:
16377036
5.

Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.

Bargieri DY, Leite JA, Lopes SC, Sbrogio-Almeida ME, Braga CJ, Ferreira LC, Soares IS, Costa FT, Rodrigues MM.

Vaccine. 2010 Apr 1;28(16):2818-26. doi: 10.1016/j.vaccine.2010.02.004.

PMID:
20170765
6.

Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies.

Mehrizi AA, Zakeri S, Rafati S, Salmanian AH, Djadid ND.

Parasite Immunol. 2011 Nov;33(11):594-608. doi: 10.1111/j.1365-3024.2011.01331.x.

7.

Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.

Xue X, Ding F, Zhang Q, Pan X, Qu L, Pan W.

Vaccine. 2010 Apr 19;28(18):3152-8. doi: 10.1016/j.vaccine.2010.02.054.

PMID:
20197139
8.

Polymorphism and epitope sharing between the alleles of merozoite surface protein-1 of Plasmodium falciparum among Indian isolates.

Mamillapalli A, Sunil S, Diwan SS, Sharma SK, Tyagi PK, Adak T, Joshi H, Malhotra P.

Malar J. 2007 Jul 20;6:95.

9.

Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine.

Angov E, Aufiero BM, Turgeon AM, Van Handenhove M, Ockenhouse CF, Kester KE, Walsh DS, McBride JS, Dubois MC, Cohen J, Haynes JD, Eckels KH, Heppner DG, Ballou WR, Diggs CL, Lyon JA.

Mol Biochem Parasitol. 2003 May;128(2):195-204.

PMID:
12742586
10.

Enhanced protection against malaria by a chimeric merozoite surface protein vaccine.

Shi Q, Lynch MM, Romero M, Burns JM Jr.

Infect Immun. 2007 Mar;75(3):1349-58.

11.

Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.

Tamborrini M, Stoffel SA, Westerfeld N, Amacker M, Theisen M, Zurbriggen R, Pluschke G.

Malar J. 2011 Dec 13;10:359. doi: 10.1186/1475-2875-10-359.

13.

Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.

Lalitha PV, Biswas S, Pillai CR, Saxena RK.

Vaccine. 2008 Aug 18;26(35):4526-35. doi: 10.1016/j.vaccine.2008.06.031.

PMID:
18590786
14.
15.

Comparative Immunogenicities of full-length Plasmodium falciparum merozoite surface protein 3 and a 24-kilodalton N-terminal fragment.

Imam M, Devi YS, Verma AK, Chauhan VS.

Clin Vaccine Immunol. 2011 Aug;18(8):1221-8. doi: 10.1128/CVI.00064-11.

16.

A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria.

Chang SP, Case SE, Gosnell WL, Hashimoto A, Kramer KJ, Tam LQ, Hashiro CQ, Nikaido CM, Gibson HL, Lee-Ng CT, Barr PJ, Yokota BT, Hut GS.

Infect Immun. 1996 Jan;64(1):253-61.

17.

Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.

Chitnis CE, Mukherjee P, Mehta S, Yazdani SS, Dhawan S, Shakri AR, Bhardwaj R, Gupta PK, Hans D, Mazumdar S, Singh B, Kumar S, Pandey G, Parulekar V, Imbault N, Shivyogi P, Godbole G, Mohan K, Leroy O, Singh K, Chauhan VS.

PLoS One. 2015 Apr 30;10(4):e0117820. doi: 10.1371/journal.pone.0117820. Erratum in: PLoS One. 2015;10(9):e0137816. Bharadwaj, Rukmini [corrected to Bhardwaj, Rukmini].

18.

IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.

Schwenk R, DeBot M, Porter M, Nikki J, Rein L, Spaccapelo R, Crisanti A, Wightman PD, Ockenhouse CF, Dutta S.

PLoS One. 2014 Oct 24;9(10):e111020. doi: 10.1371/journal.pone.0111020.

19.

Regulation of antibody specificity to Plasmodium falciparum merozoite surface protein-1 by adjuvant and MHC haplotype.

Chang SP, Nikaido CM, Hashimoto AC, Hashiro CQ, Yokota BT, Hui GS.

J Immunol. 1994 Apr 1;152(7):3483-90.

PMID:
8144929
20.

Pre-clinical assessment of novel multivalent MSP3 malaria vaccine constructs.

Bang G, Prieur E, Roussilhon C, Druilhe P.

PLoS One. 2011;6(12):e28165. doi: 10.1371/journal.pone.0028165.

Items per page

Supplemental Content

Support Center